JP2020189864A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020189864A5 JP2020189864A5 JP2020135560A JP2020135560A JP2020189864A5 JP 2020189864 A5 JP2020189864 A5 JP 2020189864A5 JP 2020135560 A JP2020135560 A JP 2020135560A JP 2020135560 A JP2020135560 A JP 2020135560A JP 2020189864 A5 JP2020189864 A5 JP 2020189864A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- use according
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 239000007864 aqueous solution Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 239000000939 antiparkinson agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 0 C[C@](Cc1cc(O)c(*)cc1)(C(O*)=O)NN Chemical compound C[C@](Cc1cc(O)c(*)cc1)(C(O*)=O)NN 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021132161A JP2021183628A (ja) | 2014-10-21 | 2021-08-16 | カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法 |
| JP2023174083A JP7688087B2 (ja) | 2014-10-21 | 2023-10-06 | カルビドパおよびｌ－ドーパプロドラッグならびにそれらの使用方法 |
| JP2025084629A JP2025118978A (ja) | 2014-10-21 | 2025-05-21 | カルビドパおよびｌ－ドーパプロドラッグならびにそれらの使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462066771P | 2014-10-21 | 2014-10-21 | |
| US62/066,771 | 2014-10-21 | ||
| JP2019139442A JP6750076B2 (ja) | 2014-10-21 | 2019-07-30 | カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019139442A Division JP6750076B2 (ja) | 2014-10-21 | 2019-07-30 | カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021132161A Division JP2021183628A (ja) | 2014-10-21 | 2021-08-16 | カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020189864A JP2020189864A (ja) | 2020-11-26 |
| JP2020189864A5 true JP2020189864A5 (enExample) | 2021-05-06 |
| JP6932227B2 JP6932227B2 (ja) | 2021-09-08 |
Family
ID=54478240
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017521517A Active JP6567049B2 (ja) | 2014-10-21 | 2015-10-21 | カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法 |
| JP2019139442A Active JP6750076B2 (ja) | 2014-10-21 | 2019-07-30 | カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法 |
| JP2020135560A Active JP6932227B2 (ja) | 2014-10-21 | 2020-08-11 | カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法 |
| JP2021132161A Pending JP2021183628A (ja) | 2014-10-21 | 2021-08-16 | カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法 |
| JP2023174083A Active JP7688087B2 (ja) | 2014-10-21 | 2023-10-06 | カルビドパおよびｌ－ドーパプロドラッグならびにそれらの使用方法 |
| JP2025084629A Pending JP2025118978A (ja) | 2014-10-21 | 2025-05-21 | カルビドパおよびｌ－ドーパプロドラッグならびにそれらの使用方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017521517A Active JP6567049B2 (ja) | 2014-10-21 | 2015-10-21 | カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法 |
| JP2019139442A Active JP6750076B2 (ja) | 2014-10-21 | 2019-07-30 | カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021132161A Pending JP2021183628A (ja) | 2014-10-21 | 2021-08-16 | カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法 |
| JP2023174083A Active JP7688087B2 (ja) | 2014-10-21 | 2023-10-06 | カルビドパおよびｌ－ドーパプロドラッグならびにそれらの使用方法 |
| JP2025084629A Pending JP2025118978A (ja) | 2014-10-21 | 2025-05-21 | カルビドパおよびｌ－ドーパプロドラッグならびにそれらの使用方法 |
Country Status (37)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2016011837A (es) | 2014-03-13 | 2017-04-27 | Neuroderm Ltd | Composiciones de inhibidores de la dopa decarboxilasa. |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| SI3209302T1 (sl) | 2014-10-21 | 2019-06-28 | Abb Vie Inc. | Predzdravila karbidope in L-dope in njihova uporaba za zdravljenje parkinsonove bolezni |
| US20190224220A1 (en) * | 2016-04-20 | 2019-07-25 | Abbvie Inc. | Carbidopa and L-Dopa Prodrugs and Methods of Use |
| US11148999B2 (en) | 2016-06-22 | 2021-10-19 | MedChem Partners, LLC | Nitric oxide donors |
| WO2018154447A1 (en) * | 2017-02-21 | 2018-08-30 | Neuroderm Ltd | Dopa decarboxylase inhibitor compositions |
| US20180311238A1 (en) * | 2017-04-28 | 2018-11-01 | Saniona A/S | Selective Agonist Of a6 Containing nAChRs |
| WO2019097120A1 (en) | 2017-11-16 | 2019-05-23 | Orion Corporation | New use and pharmaceutical dosage forms |
| CR20200225A (es) | 2017-11-24 | 2020-07-25 | H Lundbeck As | Nuevos fármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson |
| CN110294789A (zh) * | 2018-03-21 | 2019-10-01 | 海南大学 | 含多巴寡肽的合成方法及其在抗帕金森病前药方面的应用 |
| CN112770734B (zh) | 2018-09-13 | 2024-08-20 | 堪培拉大学 | 抑制方法 |
| US12251365B2 (en) | 2018-11-15 | 2025-03-18 | Abbvie Inc. | Pharmaceutical formulations for subcutaneous administration |
| WO2020178810A1 (en) * | 2019-03-04 | 2020-09-10 | Neuroderm, Ltd. | Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof |
| US11168056B2 (en) | 2019-05-20 | 2021-11-09 | H. Lundbeck A/S | Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol |
| US11111263B2 (en) | 2019-05-20 | 2021-09-07 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11104697B2 (en) | 2019-05-20 | 2021-08-31 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11130775B2 (en) | 2019-05-20 | 2021-09-28 | H. Lundbeck A/S | Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| CN113677675B (zh) | 2019-05-21 | 2024-07-26 | H.隆德贝克有限公司 | 用于治疗帕金森病的新儿茶酚胺前药 |
| JP7696829B2 (ja) | 2019-05-21 | 2025-06-23 | ハー・ルンドベック・アクチエゼルスカベット | パーキンソン病の治療に使用するためのカテコールアミンカルバメートプロドラッグ |
| CN113727979B (zh) | 2019-05-21 | 2024-09-20 | H.隆德贝克有限公司 | 用于治疗帕金森病的新儿茶酚胺前药 |
| CN119707810A (zh) | 2019-05-21 | 2025-03-28 | H.隆德贝克有限公司 | 用于治疗帕金森病的新儿茶酚胺前药 |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| EP4223288B1 (en) | 2022-02-07 | 2024-03-06 | Berlirem GmbH | Novel kit of pharmaceutical preparations for the treatment of parkinson's disease |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3132171A (en) * | 1962-06-18 | 1964-05-05 | Strong Cobb Arner Inc | 3, 4-diphosphatophenyl-alanine and process for making same |
| US4016288A (en) * | 1975-08-13 | 1977-04-05 | Merck & Co., Inc. | Compositions and method of treating hypertension |
| DD230865B1 (de) * | 1982-08-09 | 1987-05-20 | Dresden Arzneimittel | Verfahren zur herstellung von hydrazinocarbonsaeurederivaten durch n-aminierung von aminocarbonsaeurederivaten |
| US4508706A (en) * | 1983-03-30 | 1985-04-02 | Yale University | Composition for increasing melanin in mammalian skin and hair |
| US4618484A (en) | 1983-03-30 | 1986-10-21 | Yale University | Composition and method for treatment of melanomas |
| IT1213182B (it) * | 1984-06-25 | 1989-12-14 | Simes | Derivati di composti a struttura catecolamminica. |
| US4616484A (en) | 1984-11-30 | 1986-10-14 | Kysor Industrial Corporation | Vehicle refrigerant heating and cooling system |
| IT1200427B (it) | 1985-03-22 | 1989-01-18 | Afros Spa | Procedimento ed impianto per lo stampaggio di pezzi in materiale plastico espanso,con parti o inserti preformati a spruzzo nello stesso stampo di formatura |
| JPH02138A (ja) | 1987-09-18 | 1990-01-05 | Banyu Pharmaceut Co Ltd | Ｌ‐ドーパ誘導体 |
| IT1226727B (it) | 1988-07-29 | 1991-02-05 | Simes | Farmaci precursori della dopamina. |
| ATE118216T1 (de) * | 1989-04-20 | 1995-02-15 | Zambon Spa | Dopamin-medikament-vorstufe. |
| GB9102812D0 (en) | 1991-02-11 | 1991-03-27 | Enzymatix Ltd | Compounds |
| IT1255471B (it) | 1992-07-30 | 1995-11-02 | Zambon Spa | Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono |
| SE9203594D0 (sv) | 1992-11-30 | 1992-11-30 | Christer Nystroem | Laekemedel i dispersa system |
| WO1999024442A1 (en) * | 1997-11-12 | 1999-05-20 | Ariad Pharmaceuticals, Inc. | Novel signal transduction inhibitors, compositions containing them |
| US6365180B1 (en) | 1998-01-20 | 2002-04-02 | Glenn A. Meyer | Oral liquid compositions |
| US6204257B1 (en) | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
| KR20050016449A (ko) * | 2002-05-29 | 2005-02-21 | 임팩스 라보라토리즈, 인코포레이티드 | 레보도파/카르비도파의 즉시 방출 및 제어 방출 조합 투여형 |
| JPWO2004000863A1 (ja) | 2002-06-20 | 2005-10-20 | 日本水産株式会社 | プロドラッグ、その医薬としての使用、およびその製法 |
| US7101912B2 (en) | 2002-12-06 | 2006-09-05 | Xenoport, Inc. | Carbidopa prodrugs and derivatives, and compositions and uses thereof |
| WO2004069146A2 (en) | 2003-02-07 | 2004-08-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | L-dopa amide derivatives and uses thereof |
| JP5160786B2 (ja) | 2003-08-29 | 2013-03-13 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 医薬組成物及びレボドパ及びカルビドパの使用方法 |
| ES2360759T3 (es) * | 2003-08-29 | 2011-06-08 | Centocor Ortho Biotech Inc. | Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa. |
| WO2005041925A2 (en) | 2003-10-31 | 2005-05-12 | Alza Corporation | Compositions and dosage forms for enhanced absorption |
| AU2005252220B2 (en) * | 2004-06-04 | 2011-06-02 | Xenoport, Inc. | Levodopa prodrugs, and compositions and uses thereof |
| WO2006014282A2 (en) | 2004-07-06 | 2006-02-09 | Abbott Laboratories | Prodrugs of hiv protease inhibitors |
| DK1959948T3 (da) * | 2005-12-05 | 2012-08-20 | Xenoport Inc | Levodopa prodrug-mesylat, sammensætninger deraf og anvendelser deraf |
| RU2484815C2 (ru) * | 2006-05-31 | 2013-06-20 | Зольвай Фармасьютиклз Гмбх | Продолжительное 24-часовое введение в кишечник леводопа/карбидопа |
| AU2007259256A1 (en) * | 2006-06-16 | 2007-12-21 | Solvay Pharmaceuticals B.V. | Combination preparations comprising bifeprunox and L-DOPA |
| CA2673336A1 (en) | 2006-12-21 | 2008-06-26 | Xenoport, Inc. | Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use |
| GB0713189D0 (en) | 2007-07-06 | 2007-08-15 | Proximagen Ltd | Amino acid derivatives |
| BRPI0908052A2 (pt) * | 2008-02-06 | 2015-08-11 | Wockhardt Research Center | Composições farmacêuticas de entacapone, levodopa e carbidopa com biodisponibilidade melhorada |
| CN102149672A (zh) | 2008-05-20 | 2011-08-10 | 纽罗吉斯克斯公司 | 水溶性对乙酰氨基酚类似物 |
| DK3192500T3 (da) | 2009-05-19 | 2020-12-21 | Neuroderm Ltd | Sammensætninger til kontinuerlig indgivelse af dopa-decarboxylasehæmmere |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| NZ601747A (en) | 2009-11-09 | 2014-08-29 | Xenoport Inc | Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use |
| US8937151B2 (en) | 2010-03-04 | 2015-01-20 | University Of Notre Dame Du Lac | Gelatinase inhibitors and prodrugs |
| EP2640358B1 (en) | 2010-11-15 | 2018-01-03 | Neuroderm Ltd | Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same |
| DK2647619T3 (en) | 2010-12-02 | 2015-03-02 | Ono Pharmaceutical Co | NEW RELATIONSHIP AND MEDICAL USE THEREOF |
| JP2014508113A (ja) | 2010-12-10 | 2014-04-03 | シンアジャイル コーポレーション | 皮下注入可能なレボドパプロドラッグ組成物及び注入方法 |
| WO2012158527A2 (en) * | 2011-05-13 | 2012-11-22 | Howmedica Osteonics | Organophosphorous & multivalent metal compound compositions & methods |
| KR20130070371A (ko) * | 2011-12-19 | 2013-06-27 | 울산대학교 산학협력단 | 퇴행성 신경질환 예방 또는 치료용 조성물 |
| DK2968218T3 (da) | 2013-03-13 | 2021-09-20 | Neuroderm Ltd | Kombination til behandling af parkinsons sygdom |
| EP2994453A4 (en) | 2013-03-15 | 2017-04-12 | Techfields Pharma Co., Ltd. | Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases |
| SI3209302T1 (sl) | 2014-10-21 | 2019-06-28 | Abb Vie Inc. | Predzdravila karbidope in L-dope in njihova uporaba za zdravljenje parkinsonove bolezni |
| MA41377A (fr) | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
| US20190224220A1 (en) | 2016-04-20 | 2019-07-25 | Abbvie Inc. | Carbidopa and L-Dopa Prodrugs and Methods of Use |
| EP3518920A1 (en) | 2016-09-29 | 2019-08-07 | Berlirem GmbH | L-dopa derivatives for the treatment of neurological diseases |
| WO2018154447A1 (en) | 2017-02-21 | 2018-08-30 | Neuroderm Ltd | Dopa decarboxylase inhibitor compositions |
-
2015
- 2015-10-21 SI SI201530761T patent/SI3209302T1/sl unknown
- 2015-10-21 CN CN202010250046.4A patent/CN111454290B/zh active Active
- 2015-10-21 KR KR1020247023761A patent/KR20240113982A/ko active Pending
- 2015-10-21 PL PL15791424T patent/PL3209302T3/pl unknown
- 2015-10-21 LT LTEP15791424.3T patent/LT3209302T/lt unknown
- 2015-10-21 US US14/919,418 patent/US9446059B2/en active Active
- 2015-10-21 CN CN202010123543.8A patent/CN111362980B/zh active Active
- 2015-10-21 TW TW104134601A patent/TWI718999B/zh active
- 2015-10-21 RS RS20190854A patent/RS58972B1/sr unknown
- 2015-10-21 MX MX2021003840A patent/MX393568B/es unknown
- 2015-10-21 RU RU2017117413A patent/RU2743347C2/ru active
- 2015-10-21 WO PCT/US2015/056686 patent/WO2016065019A1/en not_active Ceased
- 2015-10-21 CA CA2965379A patent/CA2965379A1/en not_active Abandoned
- 2015-10-21 JP JP2017521517A patent/JP6567049B2/ja active Active
- 2015-10-21 AU AU2015335941A patent/AU2015335941B2/en active Active
- 2015-10-21 ES ES15791424T patent/ES2739536T3/es active Active
- 2015-10-21 EP EP19164151.3A patent/EP3569587A1/en not_active Withdrawn
- 2015-10-21 MX MX2017005236A patent/MX381069B/es unknown
- 2015-10-21 KR KR1020237015051A patent/KR20230066484A/ko not_active Ceased
- 2015-10-21 AR ARP150103412A patent/AR102389A1/es unknown
- 2015-10-21 CN CN202010250040.7A patent/CN111494395B/zh active Active
- 2015-10-21 BR BR112017008198-9A patent/BR112017008198B1/pt active IP Right Grant
- 2015-10-21 TR TR2019/08296T patent/TR201908296T4/tr unknown
- 2015-10-21 RU RU2021103000A patent/RU2021103000A/ru unknown
- 2015-10-21 SG SG11201703170RA patent/SG11201703170RA/en unknown
- 2015-10-21 HR HRP20191285TT patent/HRP20191285T1/hr unknown
- 2015-10-21 KR KR1020177013734A patent/KR102537018B1/ko active Active
- 2015-10-21 EP EP15791424.3A patent/EP3209302B1/en active Active
- 2015-10-21 MY MYPI2017701367A patent/MY189519A/en unknown
- 2015-10-21 HU HUE15791424 patent/HUE044115T2/hu unknown
- 2015-10-21 TW TW110101738A patent/TWI755257B/zh active
- 2015-10-21 UA UAA201704815A patent/UA120437C2/uk unknown
- 2015-10-21 PT PT15791424T patent/PT3209302T/pt unknown
- 2015-10-21 SM SM20190376T patent/SMT201900376T1/it unknown
- 2015-10-21 CN CN201580069519.8A patent/CN107206013A/zh active Pending
- 2015-10-21 DK DK15791424.3T patent/DK3209302T3/da active
- 2015-10-21 EP EP22204022.2A patent/EP4186510A1/en active Pending
-
2016
- 2016-07-21 US US15/216,009 patent/US20160362431A1/en not_active Abandoned
-
2017
- 2017-04-19 ZA ZA2017/02760A patent/ZA201702760B/en unknown
- 2017-04-20 SA SA521421115A patent/SA521421115B1/ar unknown
- 2017-04-20 IL IL251829A patent/IL251829B/en active IP Right Grant
- 2017-04-21 PH PH12017500746A patent/PH12017500746B1/en unknown
- 2017-09-26 US US15/715,245 patent/US10174061B2/en active Active
-
2018
- 2018-12-05 US US16/210,996 patent/US10730895B2/en active Active
-
2019
- 2019-07-19 CY CY20191100771T patent/CY1121826T1/el unknown
- 2019-07-30 JP JP2019139442A patent/JP6750076B2/ja active Active
- 2019-08-23 IL IL268885A patent/IL268885B/en active IP Right Grant
-
2020
- 2020-05-04 US US16/866,400 patent/US11091507B2/en not_active Expired - Fee Related
- 2020-08-04 IL IL276493A patent/IL276493A/en unknown
- 2020-08-11 JP JP2020135560A patent/JP6932227B2/ja active Active
-
2021
- 2021-03-04 AU AU2021201414A patent/AU2021201414B2/en active Active
- 2021-07-16 US US17/378,321 patent/US20220153765A1/en not_active Abandoned
- 2021-08-16 JP JP2021132161A patent/JP2021183628A/ja active Pending
-
2022
- 2022-10-24 US US17/971,836 patent/US20230106081A1/en not_active Abandoned
-
2023
- 2023-02-20 HU HUS2300009C patent/HUS2300009I1/hu unknown
- 2023-03-07 CY CY2023010C patent/CY2023010I2/el unknown
- 2023-03-20 NO NO2023013C patent/NO2023013I1/no unknown
- 2023-03-24 NL NL301224C patent/NL301224I2/nl unknown
- 2023-03-31 FI FIC20230014C patent/FIC20230014I1/fi unknown
- 2023-04-03 LU LU00304C patent/LUC00304I2/fr unknown
- 2023-06-08 LT LTPA2023519C patent/LTC3209302I2/lt unknown
- 2023-08-04 AU AU2023210650A patent/AU2023210650A1/en not_active Abandoned
- 2023-09-29 FR FR23C1035C patent/FR23C1035I2/fr active Active
- 2023-10-06 JP JP2023174083A patent/JP7688087B2/ja active Active
-
2025
- 2025-05-21 JP JP2025084629A patent/JP2025118978A/ja active Pending
- 2025-09-25 AU AU2025238004A patent/AU2025238004A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020189864A5 (enExample) | ||
| CN1161113C (zh) | 氨基硫醇化合物用于制备治疗神经、肾疾病和治疗毒性的药物 | |
| US20230128449A1 (en) | Silicate containing compositions and methods of treatment | |
| JP2019515908A5 (enExample) | ||
| EP2458996A1 (en) | Novel oral forms of a phosphonic acid derivative | |
| JP2004531516A5 (enExample) | ||
| JP2003509349A5 (enExample) | ||
| CA2446622C (en) | Isostearic acid salts as permeation enhancers | |
| RU2004131214A (ru) | Способы лечения когнитивных расстройств | |
| CN111346081B (zh) | 包含正戊酸、吲哚丙酸和正丁酸钠的药物组合物的新用途 | |
| WO2000007605A1 (fr) | Utilisation de derives de la camptothecine, avec une toxicite gastro-intestinale reduite | |
| RU2440113C2 (ru) | Фармацевтическая композиция для инъекционного особенно целенаправленного местного применения | |
| JP2001508769A (ja) | アレンドロン酸塩及び胃排出を促進する薬剤を含有する医薬組成物 | |
| US20080293648A1 (en) | Compositions and Methods for Cancer Treatment | |
| JP4078397B2 (ja) | 下痢の予防及び治療剤 | |
| US20100144676A1 (en) | Oleyl phosphocholine | |
| Anderson et al. | The treatment of pulmonary edema in the absence of renal function: a role for sorbitol and furosemide | |
| JP2000219626A (ja) | ケロイドおよび／または肥厚性瘢痕の治療剤 | |
| BE890453A (fr) | Procede d'inhibition des metastases de cellules tumorales | |
| JP7130879B2 (ja) | ベンゾアゼピン化合物含有医薬組成物 | |
| JPH10226646A (ja) | パーキンソニズム治療剤 | |
| JP2006518722A (ja) | 膵臓癌、軟部組織の肉腫、精巣腫瘍、リンパ腫、胸腺腫、ウィルムス腫瘍、腎臓癌、黒色腫、肺腫瘍、脳内転移、頭頸部の腫瘍、および乳癌の処置のための、１−（２−クロロエチル）−１−ニトロソ−３−（２−ヒドロキシエチル）ウレアの使用方法 | |
| WO1994028892A1 (en) | Inhibitor for rejection accompanying organ transplantation | |
| EP4065129A1 (fr) | Utilisation de composés pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes | |
| JP2843944B2 (ja) | 利胆剤 |